Detalhe da pesquisa
1.
An expanded universe of cancer targets.
Cell
; 184(5): 1142-1155, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667368
2.
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Annu Rev Pharmacol Toxicol
; 64: 455-479, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738504
3.
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.
Genome Res
; 31(5): 747-761, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707228
4.
Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Blood
; 140(6): 644-658, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35482940
5.
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß-chain cytokine receptor endocytosis.
Blood
; 139(5): 761-778, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780648
6.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
7.
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
Br J Haematol
; 200(3): 323-328, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264026
8.
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Blood
; 137(7): 939-944, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32898857
9.
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Haematologica
; 108(6): 1567-1578, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727397
10.
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
Am J Hematol
; 98(11): 1762-1771, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647134
11.
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 117(24): 13670-13679, 2020 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32471953
12.
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 117(25): 14331-14341, 2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513686
13.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
14.
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Blood
; 135(24): 2159-2170, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315394
15.
Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 116(49): 24593-24599, 2019 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31754026
16.
Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Blood
; 133(14): 1597-1606, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30692122
17.
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.
Blood
; 134(11): 867-879, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31366621
18.
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Invest New Drugs
; 39(3): 736-746, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403501
19.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med
; 376(10): 917-927, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273028
20.
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.
Proc Natl Acad Sci U S A
; 114(44): 11751-11756, 2017 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29078326